23 results

• FDA Removes Heart Attack, Stroke Warnings From Testosterone Drug Labels

  March 4, 2025

  Irvin Jackson

  Federal regulators are removing heart attack and stroke warnings from testosterone treatments following new studies that failed to find heart risks.

• Study Finds Low Dose Aspirin Fails to Prevent Strokes, Increases Bleeding Risks from Falls

  August 9, 2023

  Martha Garcia

  A new study finds that older adults on a daily low-dose aspirin regimen are not getting additional protection from strokes, and may be increasing their risk of brain bleeds.

• Link Between Testosterone Drugs and Heart Risks Not Found in New Study

  June 19, 2023

  Irvin Jackson

  A new study indicates testosterone drugs were as safe as a placebo when it came to heart risks.

• FDA Worried Jakafi May Have Cancer, Heart Risks Similar to Xeljanz

  June 10, 2021

  Irvin Jackson

  The FDA has delayed an expanded approval for the drug Jakafi, potentially due to concerns over heart and cancer risks linked to Pfizer's Xeljanz, a similar drug.

• Speculation Mounts for Potential FDA Panel Review of Health Risks from Xeljanz, Other JAK Inhibitors

  April 14, 2021

  Irvin Jackson

  Some believe the FDA is preparing to review the risks and benefits of Xeljanz and similar drugs given recent cancer and heart concerns.

• Investigation of Xeljanz Cancer and Heart Risks Launched in Canada

  April 8, 2021

  Irvin Jackson

  Growing concerns have led to Health Canada announcing a Xeljanz safety review, to determine whether more warnings or actions are needed following studies suggesting the ulcerative colitis drug could increase the risk of cancer and heart attacks.

• Xeljanz Cancer Warnings Leave More Questions Than Answers

  March 24, 2021

  Irvin Jackson

  New Xeljanz research links the drug to cancer risks, but has not yet led to a warning for users as to which types of cancer they may face.

• Pfizer Files Lawsuit Over Xeljanz Generic Application

  March 5, 2021

  Austin Kirk

  Pfizer filed a patent lawsuit over an alleged attempt to create a generic version of Xeljanz shortly after the FDA announced new concerns about the drug's safety.

• Xeljanz Problems Highlighted in Study Data May Lead to New FDA Restrictions: Report

  February 8, 2021

  Irvin Jackson

  The FDA is weighing new restrictions on Xeljanz, following clinical trial data linking the drug to an increased risk of heart problems and cancer, according to a new report.

• Xeljanz Side Effects May Increase Risk of Cancer, Serious Heart Problems: FDA Alert

  February 5, 2021

  Russell Maas

  A new FDA warning indicates Xeljanz side effects may increase the risk of heart problems, including heart attacks, and cancer in patients over 50.